Prelude Therapeutics Incorporated (PRLD)
| Market Cap | 472.60M +835.7% |
| Revenue (ttm) | 12.14M +73.4% |
| Net Income | -99.50M |
| EPS | -1.29 |
| Shares Out | 100.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 865,216 |
| Open | 4.880 |
| Previous Close | 4.400 |
| Day's Range | 4.435 - 4.881 |
| 52-Week Range | 0.730 - 5.540 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 4.67 (-0.64%) |
| Earnings Date | May 13, 2026 |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCel... [Read more]
Financial Performance
In 2025, Prelude Therapeutics's revenue was $12.14 million, an increase of 73.43% compared to the previous year's $7.00 million. Losses were -$99.50 million, -21.76% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PRLD stock is "Strong Buy." The 12-month stock price target is $4.67, which is a decrease of -0.64% from the latest price.
News
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pri...
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today anno...
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company'...
Prelude Therapeutics Transcript: Conference
The company has shifted its focus to JAK2V617F and KAT6A programs, targeting clinical entry in 2026, and is advancing a novel CALR degrader. Mutant-selective approaches and strategic partnerships, including a deal with Incyte, support a strong financial runway into 2027.
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycyth...
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) cle...
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Prelude Therapeut...
Prelude Therapeutics Earnings Call Transcript: Q3 2025
Secured $60M upfront and up to $910M in total from Incyte for the JAK2 V617F program, supporting clinical advancement of two lead oncology assets into 2026–2027. Both programs target large, high-need markets with differentiated, selective approaches and robust preclinical data.
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $PRLD--PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm.
Prelude Therapeutics Announces Strategic Business Update
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617...
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients...
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publ...
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
WILMINGTON, Del., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Katina Dorton to i...
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial c...
Prelude Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference
Clinical programs for SMARCA2 degraders are advancing, with IV and oral agents showing promising efficacy and safety, especially in lung and upper GI cancers. The pipeline includes a selective CDK6 degrader and ADC collaborations, supported by a strong cash position into 2026.
Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2025
Lead SMARCA2 programs show promising safety and efficacy, with both IV and oral candidates advancing quickly in aggressive cancer types. Pipeline expansion includes a selective CAT6A degrader and antibody conjugates, with strong preclinical data and new clinical milestones expected in 2024–2025.
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will parti...
Prelude Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025
Advancing SMARCA2 and KAT6A degrader programs, with strong early efficacy and rapid clinical progress. Oral and IV assets are being developed in parallel, supported by a solid cash position and active business development. Regulatory outlook remains positive.
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prel...
Prelude Therapeutics to Participate in Citizens Life Sciences Conference
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will partic...
Prelude Announces Presentations at 2025 AACR Annual Meeting
Preclinical data elucidating the mechanism of action of PRT3789, Prelude's first-in-class, highly selective SMARCA2 degrader currently in early clinical development
Prelude Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference
Current macro and regulatory changes are not expected to disrupt operations, with proactive supply chain management in place. Lead SMARCA pathway degraders show promising early clinical results, and both IV and oral programs are advancing, with a major data update expected in H2 2025.